Literature DB >> 27171354

Intraocular Lymphoma Models.

Mary E Aronow1, Defen Shen1, Jacob Hochman2, Chi-Chao Chan1.   

Abstract

Primary vitreoretinal lymphoma (PVRL) is a subtype of primary central nervous system lymphoma (PCNSL), a high-grade, extranodal, non-Hodgkin's lymphoma, predominantly of B-cell origin. PVRL is an aggressive disease with a poor prognosis. Human studies are not ideally suited for the study of intraocular lymphoma pathogenesis or treatment strategies due to the rare nature of the disease, its variable presentation, limited volume of available ocular fluids, and fragility of sampled lymphoma cells. Animal models have been critical in making progress in understanding intraocular lymphoma pathogenesis and investigating potential therapeutic strategies. Early murine models for intraocular lymphoma used intraperitoneal injection of mouse T-cell lymphomas. This was followed by intravitreal T-cell murine models. More recent murine models have used B-cell lymphomas to more closely mimic human disease. The most current B-cell lymphoma models employ a combined approach of inoculating both the mouse vitreous cavity and brain. The challenge in murine models for intraocular lymphoma lies in recreating the clinical features, disease behavior, molecular profile, systemic immunity, and the microenvironment observed in human disease. In the future, animal models will continue to be central to furthering our understanding of the disease and in the investigation of potential treatment targets.

Entities:  

Keywords:  B-cell lymphoma; Experimental model; Eye; Lymphoma; Mouse; Primary vitreoretinal lymphoma; T-cell lymphoma

Year:  2015        PMID: 27171354      PMCID: PMC4847663          DOI: 10.1159/000370158

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  37 in total

1.  Two successive ocular malignancies in the same eye of a HIV-positive patient: a case report.

Authors:  Kalpana Babu; Krishna R Murthy; Subramanian Krishnakumar
Journal:  Ocul Immunol Inflamm       Date:  2010-04       Impact factor: 3.070

2.  Ocular and central nervous system lymphoma: clinical features and diagnosis.

Authors:  N Cassoux; H Merle-Beral; V Leblond; B Bodaghi; D Miléa; S Gerber; C Fardeau; I Reux; K H Xuan; C C Chan; P LeHoang
Journal:  Ocul Immunol Inflamm       Date:  2000-12       Impact factor: 3.070

3.  Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management.

Authors:  D H Char; B M Ljung; T Miller; T Phillips
Journal:  Ophthalmology       Date:  1988-05       Impact factor: 12.079

Review 4.  Primary central nervous system lymphoma.

Authors:  L M DeAngelis
Journal:  Curr Opin Neurol       Date:  1999-12       Impact factor: 5.710

5.  Systemic non-Hodgkin's lymphoma masquerading as Vogt-Koyanagi-Harada disease in an HIV-positive patient.

Authors:  Annie Mathai; Ashish Lall; Rajeev Jain; Avinash Pathengay
Journal:  Clin Exp Ophthalmol       Date:  2006-04       Impact factor: 4.207

6.  Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes.

Authors:  E K Akpek; I Ahmed; F H Hochberg; M Soheilian; T P Dryja; F A Jakobiec; C S Foster
Journal:  Ophthalmology       Date:  1999-09       Impact factor: 12.079

7.  HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.

Authors:  Sookhee Bang; Satoshi Nagata; Masanori Onda; Robert J Kreitman; Ira Pastan
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

8.  Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.

Authors:  Rym Ben Abdelwahed; Sabrina Donnou; Hanane Ouakrim; Lucile Crozet; Jérémie Cosette; Alexandra Jacquet; Isabel Tourais; Bénédicte Fournès; Mélanie Gillard Bocquet; Amine Miloudi; Valérie Touitou; Cécile Daussy; Marie-Christine Naud; Wolf Herman Fridman; Catherine Sautès-Fridman; Rémi Urbain; Sylvain Fisson
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-05-01       Impact factor: 4.799

9.  The clinical spectrum of ocular lymphoma.

Authors:  K Peterson; K B Gordon; M H Heinemann; L M DeAngelis
Journal:  Cancer       Date:  1993-08-01       Impact factor: 6.860

Review 10.  Primary central nervous system lymphoma.

Authors:  F H Hochberg; D C Miller
Journal:  J Neurosurg       Date:  1988-06       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.